Boston Scientific Corporation
HealthcareNYSE:BSX · New York Stock Exchange
-$0.23 today
Vol 9.43M · Avg 18.98M
Income Statement
Follow revenue through to earnings
Review sales, margins, expenses, and profit trends to see what is actually driving reported earnings over time.
Earnings Waterfall
Revenue to Net Income
Key Ratios
Analysis
$20.6B of revenue converted into $3.6B of net income for the selected period. Gross margin is 70.4% and net margin is 17.2%, showing how much revenue survives after costs and taxes. EPS is $2.38, tying the income statement back to per-share earnings.
Income Statement
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $20.1B +19.9% | $16.7B +17.6% | $14.2B +12.3% | $12.7B +6.7% | $11.9B | $809.6M | $921.6M | $731.2M |
| Cost of Revenue | $6.2B -4.0% | $6.5B +19.8% | $5.4B +8.9% | $5.0B +12.2% | $4.4B | $725.6M | $804.0M | $882.4M |
| Gross Profit | $13.9B +34.9% | $10.3B +16.3% | $8.8B +14.5% | $7.7B +3.4% | $7.5B | $8.9B | $7.6B | $6.2B |
| Gross Margin | 69.0% +7.7pp | 61.3% -0.7pp | 62.0% +1.2pp | 60.8% -1.9pp | 62.8% | 9.8% | 28.9% | 38.3% |
| Research & Development | $2.1B +27.1% | $1.6B +14.2% | $1.4B +6.9% | $1.3B +9.9% | $1.2B | $983.2M | $1.3B | $490.4M |
| Selling, General & Admin | $6.9B +15.1% | $6.0B +15.3% | $5.2B +14.8% | $4.5B +5.5% | $4.3B | $620.6M | $923.0M | -$1.5B |
| Operating Expenses | $9.9B +29.5% | $7.6B +14.8% | $6.7B +12.9% | $5.9B +6.3% | $5.5B | $5.3B | $7.0B | $8.7B |
| Depreciation & Amortization | $0 -100.0% | $1.3B +6.1% | $1.2B +5.3% | $1.1B +3.9% | $1.1B | $374.2M | $1.2B | $631.8M |
| EBITDA | $3.7B -5.2% | $3.9B +14.0% | $3.5B +26.0% | $2.7B +8.9% | $2.5B | -$15.2B | $6.8B | $9.3B |
| EBITDA Margin | 18.6% -4.9pp | 23.5% -0.7pp | 24.2% +2.6pp | 21.6% +0.4pp | 21.2% | 5.6% | 46.3% | 42.0% |
| Operating Income | $4.0B +50.7% | $2.6B +20.8% | $2.2B +19.6% | $1.8B -5.1% | $1.9B | $12.3B | $14.0B | -$15.7B |
| Operating Margin | 19.8% +4.0pp | 15.7% +0.4pp | 15.3% +0.9pp | 14.4% -1.8pp | 16.2% | 16.6% | 24.1% | 22.0% |
| Interest Income | $0 -100.0% | $107.0M +386.4% | $22.0M +120.0% | $10.0M +150.0% | $4.0M | -$1.5B | -$1.6B | $405.0M |
| Interest Expense | $349.0M -9.8% | $387.0M +42.3% | $272.0M -41.4% | $464.0M +33.0% | $349.0M | $1.1B | $1.0B | $1.2B |
| Other Income / Expenses | -$586.0M -66.0% | -$353.0M -80.1% | -$196.0M +71.3% | -$683.0M +19.3% | -$846.0M | -$1.5B | $1.4B | $1.2B |
| Income Before Tax | $3.4B +48.3% | $2.3B +15.0% | $2.0B +74.0% | $1.1B +6.0% | $1.1B | $3.3B | $4.9B | $3.6B |
| Pre-Tax Margin | 16.9% +3.2pp | 13.6% -0.3pp | 13.9% +4.9pp | 9.0% -0.1pp | 9.1% | 20.8% | 18.7% | 26.2% |
| Income Tax Expense | $493.0M +13.1% | $436.0M +10.9% | $393.0M -11.3% | $443.0M +1130.6% | $36.0M | $1.3B | -$1.6B | $745.2M |
| Net Income | $2.9B +55.7% | $1.9B +16.4% | $1.6B +128.2% | $698.0M -32.9% | $1.0B | $4.9B | $4.8B | $4.7B |
| Net Margin | 14.4% +3.3pp | 11.1% -0.1pp | 11.2% +5.7pp | 5.5% -3.2pp | 8.7% | 12.4% | 17.5% | 22.5% |
| EPS (Basic) | $2 +55.6% | $1 +16.6% | $1 +140.8% | $0 -35.2% | $1 | $400.8M | $703.2M | $1.3B |
| EPS (Diluted) | $2 +55.2% | $1 +16.5% | $1 +140.6% | $0 -35.1% | $1 | $766.2M | $609.4M | $452.6M |
| Weighted Avg Shares | $1.5B +0.6% | $1.5B +1.3% | $1.5B +1.6% | $1.4B +0.6% | $1.4B | $757.8M | $925.8M | $1.1B |
| Weighted Avg Shares (Diluted) | $1.5B +0.6% | $1.5B +1.5% | $1.5B +1.7% | $1.4B +0.4% | $1.4B | $1.2B | $924.4M | $678.0M |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
Amgen Inc.
NASDAQ:AMGN
$190.57B
Gilead Sciences, Inc.
NASDAQ:GILD
$155.42B
Abbott Laboratories
NYSE:ABT
$152.37B
Pfizer Inc.
NYSE:PFE
$149.13B
Danaher Corporation
NYSE:DHR
$127.49B
Stryker Corporation
NYSE:SYK
$119.98B
Sanofi
NASDAQ:SNY
$106.49B
Medtronic plc
NYSE:MDT
$102.95B
McKesson Corporation
NYSE:MCK
$94.97B
HCA Healthcare, Inc.
NYSE:HCA
$85.93B
SEC Filings
Recent regulatory filings
No filings found.
How much revenue does BSX generate?
Boston Scientific Corporation (BSX) reported $20.07B of revenue in fiscal 2025.
Is BSX profitable?
Boston Scientific Corporation (BSX) reported $2.89B of net income, with a net margin of 14.4%.
Explore More
Continue the stock analysis
Jump to another research area for this company.